Trial Profile

A Proof-of-concept Trial With Safety Run of Tepotinib and Pembrolizumab in NSCLC Patients With and Without MET Exon 14 Mutations (POTENT)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tepotinib (Primary)
Indications Non-small cell lung cancer
Focus Proof of concept; Therapeutic Use
Acronyms POTENT

Most Recent Events

20 Aug 2025 Planned End Date changed from 1 Feb 2028 to 9 Jan 2029.
20 Aug 2025 Planned primary completion date changed from 1 Feb 2028 to 8 Mar 2028.
15 Aug 2025 Planned number of patients changed from 38 to 19.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com